• On sale!
  • Out-of-Stock

VIVIDRIN EYES * COLL6ML0.5MG / ML

  • Bausch + Lomb Ireland Limited
  • 048127017
Vividrin Occhi is a drug based on the active ingredient azelastine hydrochloride, belonging to the category of Antiallergics and specifically Other antiallergics. Vividrin Eyes can be prescribed with SOP Recipe - non-prescription medicine. Treatment and prevention of symptoms of seasonal allergic conjunctivitis in adults and children aged 4 years and above Treatment of symptoms of non-seasonal (perennial) allergic conjunctivitis in adults and children aged 12 years and older.
info_outline View product sheet
Final Price €16.50
error Out-of-Stock

Notify me when available

  Convenient and safe payments

Even with a credit card

  Shipping in 24h all over the world

Fast and safe international shipping worldwide

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service. Experts in international shipping

Other products Others products at unbeatable price

Bausch + Lomb Ireland Limited

Discover all products

VIVIDRIN EYES * COLL6ML0.5MG / ML

Therapeutic indications

Treatment and prevention of symptoms of seasonal allergic conjunctivitis in adults and children aged 4 years and over. Treatment of symptoms of non-seasonal (perennial) allergic conjunctivitis in adults and children aged 12 years and older.

Dosage and method of use

Dosage. Seasonal allergic conjunctivitis:The usual dosage in adults and children aged 4 years and over is one drop per eye, twice a day, which can be increased up to four times a day if necessary. If subsequent exposure to allergens is known in advance, Vividrin Occhi should be administered prophylactically, prior to exposure.Non-seasonal (perennial) allergic conjunctivitis:The usual dosage in adults and children aged 12 years and over is one drop per eye twice a day, which can be increased up to four times a day if necessary. As safety and efficacy have been demonstrated in clinical studies for periods of up to 6 weeks, the duration of each treatment should be limited to a maximum of 6 weeks.Note for self-medication:The patient should be informed that the treatment of seasonal allergic conjunctivitis for more than 6 weeks should only be carried out under the supervision of a physician. It is recommended that you contact your doctor if your symptoms worsen or do not improve after 48 hours.Method of administration:Ophthalmic use. The eye drops should be applied into the conjunctival sac by slightly tilting the head back. The eye drops should always be used avoiding contact of the bottle tip with the eye or skin.

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Side effects

The assessment of undesirable effects is based on the following frequencies: Very common (≥1 / 10), Common (≥1 / 100, Reporting of suspected adverse reactions: Reporting of suspected adverse reactions occurring after authorization of the medicinal product is important , as it allows continuous monitoring of the benefit / risk ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.aifa.gov.it/content/segnalazioni-reazioni- adverse.

Special warnings

Vividrin Occhi is not indicated for the treatment of eye infections. This medicinal product contains 0.0035 mg of benzalkonium chloride per drop, equivalent to 0.125 mg / ml. Benzalkonium chloride can be absorbed by soft contact lenses and can lead to a change in their color. Patients should be advised to remove contact lenses before using this medicine and to wait at least 15 minutes before reapplying. Benzalkonium chloride has been indicated as a cause of eye irritation, dry eye, film and corneal surface alteration. To be used with caution in patients with dry eye and corneal compromise. Patients should be monitored for prolonged use.

Pregnancy and breastfeeding

Pregnancy:There is insufficient information available to establish the safety of azelastine during human pregnancy. At high oral doses azelastine has been shown to induce adverse effects (fetal death, growth retardation and skeletal malformation) in laboratory animals. Local ocular application will lead to minimal systemic exposure (in the range of picograms). However, caution should be exercised when using Vividrin Eyes during pregnancy.Feeding time:Azelastine is excreted in breast milk in low quantities. For this reason, Vividrin Occhi is not recommended while breastfeeding.Fertility:In animal studies at higher than therapeutic oral doses of azelastine, the fertility index decreased (see section 5.3).

Expiration and retention

Do not store above 25 ° C. Keep the bottle in the original package to protect the medicine from light.

Interactions with other drugs

No specific interaction studies have been conducted with azelastine hydrochloride. Interaction studies have been conducted with high doses of oral azelastine, although they are of no relevance to Vividrin Eyes, as systemic levels of the drug are in the picogram range after administration of the eye drops.

Overdose

No specific reactions are known after ocular overdose and, with the ocular route of administration, no overdose reactions are expected. There is no experience with the administration of toxic doses of azelastine hydrochloride in humans. In the event of overdose or intoxication, central nervous system disorders are to be expected based on the results in experimental animals. Treatment of these disorders must be symptomatic. There is no known antidote.

Active principles

Each ml of solution contains 0.5 mg of azelastine hydrochloride. One drop contains 0.015 mg of azelastine hydrochloride. Excipients with known effect: 1 ml of eye drops contains 0.125 mg of benzalkonium chloride. For the full list of excipients, see section 6.1.

Excipients

Benzalkonium chloride; Disodium edetate; Hypromellose; Liquid sorbitol 70% (not crystallizable); Sodium hydroxide (for pH adjustment); Water for injections.

048127017

Data sheet

Packaging
0.5 mg / ml eye drops solution 1 bottle 6 ml
Product Type
HUMAN DRUG
ATC code
S01GX07
ATC description
Azelastine
Therapeutic Group
Antiallergic
Active principle
azelastine hydrochloride
Class
C.
Pharmaceutical form
eye drops
Type of Administration
ophthalmic
Container
vial
Quantity
1 vial / vial / vial
Capacity
6 milliliters
Quantity of the Active Ingredient
, 5MG
Recipe required
SOP - non-prescription medicine
chat Comments (0)